/
MEDICATION ASSISTED TREATMENT (MAT) MEDICATION ASSISTED TREATMENT (MAT)

MEDICATION ASSISTED TREATMENT (MAT) - PowerPoint Presentation

karlyn-bohler
karlyn-bohler . @karlyn-bohler
Follow
387 views
Uploaded On 2018-09-20

MEDICATION ASSISTED TREATMENT (MAT) - PPT Presentation

Presented by NJATOD Officers Barbara Schlichting NJATOD Secretary Somerset Treatment Services Christie Hanvey NJATOD Vice President Spectrum Healthcare Center Maiysha Ware NJATOD President The ID: 673149

treatment mat opioid methadone mat treatment methadone opioid medication buprenorphine drug addiction patients recovery services medications counseling health maintenance

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "MEDICATION ASSISTED TREATMENT (MAT)" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

MEDICATION ASSISTED TREATMENT (MAT)

Presented by:

NJATOD Officers

Barbara

Schlichting

, NJATOD Secretary, Somerset Treatment Services

Christie

Hanvey

, NJATOD Vice President, Spectrum Healthcare Center

Maiysha

Ware, NJATOD President, The

Lennard

ClinicSlide2

WHAT IS MEDICATION ASSISTED TREATMENT?

U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment defines MAT as:

A

ny treatment for

opioid

addiction that includes a medication (e.g., methadone,

buprenorphine

,

naltrexone

) approved by the U.S. Food and Drug Administration (FDA) for

opioid

addiction detoxification or maintenance treatment. MAT may be provided in an OTP or an OTP medication unit (e.g., pharmacy, physician’s office) or for

buprenorphine

a physician’s office or other healthcare setting. Comprehensive maintenance, medical maintenance, interim maintenance, detoxification, and medically supervised withdrawal are types of MAT. Slide3

MAT is…

MAT

combines the use of medication and behavioral therapy to treat substance use disorder.

FDA approved medications used in MAT: Methadone, Buprenorphine & Naltrexone.

MAT combines counseling with medications that block opioids’ euphoric effects and relieve relapse inducing cravings.

MAT increase patient engagement and retention in treatment, decrease drug use, infectious disease transmission and criminal activity. Slide4

Methadone

What is methadone?

Methadone is an opioid medication. Methadone reduces withdrawal symptoms in people addicted to heroin or other narcotic drugs without causing the "high" associated with the drug addiction. Methadone is used as part of drug addiction detoxification or maintenance program.

FDA Approved since 1947.

Pregnancy Category “C” Safe to use during pregnancy.

Half-life of Methadone is between 12-18 hours.

The effects of Methadone last between 24-36 hours.

Methadone is a full agonist, it fully binding to the mu receptors in the brain alleviating symptoms of withdrawal and or cravings, while blocking the effects of other opioids (when at blocking dose). Slide5

Buprenorphine

What is Buprenorphine (Suboxone)?

Suboxone contains a combination of buprenorphine and naloxone. Buprenorphine is an opioid medication. Naloxone blocks the effects of opioid medication, including pain relief or feelings of well-being that can lead to opioid abuse. Buprenorphine is approved for use in both induction and maintenance treatment of opioid dependence in appropriate patients.

FDA Approved for clinical use since 2002.

Pregnancy Category “C” Safe to use during pregnancy.

Buprenorphine is a partial agonist, it is a combination of an agonist and antagonist. As a partial agonist it binds to the mu receptor in the brain and can alleviate withdrawal and or craving, but has the added antagonist properties of preventing other opioids from stimulating the receptor. Partial agonist are less likely to be abused. Slide6

Naltrexone

What is Naltrexone (Vivitrol)?

Vivitrol is the first and only non-addictive, once-monthly medication that, when combined with counseling, is proven to help prevent relapse to opioid dependence, after detox. Vivitrol blocks opioid receptors in the brain while you work with the psychological aspects of counseling.

Vivitrol injection is used to prevent relapse in people who became dependent on opioid medicine and then stopped using it. Naltrexone can help keep you from feeling a "need" to use the opioid.

Vivitrol injection is also used to treat alcoholism by reducing your urge to drink alcohol. This may help you drink less or stop drinking altogether.

FDA Approved for OUD in 2010.

Pregnancy Category “C” Safe to use during pregnancy.

The effects of Naltrexone last for 28 days.

Naltrexone is a antagonist, antagonists bind to the mu opioid receptors but don’t stimulate the production of endorphins.  Antagonist prevent other opioids from stimulating the mu receptors. Slide7

Medication Comparisons

Methadone and buprenorphine are both safe and effective for mothers and babies

Buprenorphine use results in milder NAS symptoms, shorter hospital stays, and less morphine in tapering.

Methadone has a significantly higher retention rate during pregnancy and after childbirth, and longer recovery outcomes for the mother.

Methadone’s impact on children’s health has been studied for 40 years with no developmental impact detected.

There is inadequate data on buprenorphine’s long-term effect on children. Slide8

A few more…

Methadone does not have a “ceiling effect” like buprenorphine. Buprenorphine is effective only to 16mgs. Anything above that is a placebo.

Methadone is cheaper.

Methadone is only available through the OTP.

Buprenorphine is available through both an OTP and a private physician.

Methadone treatment is highly structured with both medical and clinical components

.

Methadone

is associated with better treatment outcomes because of the high activity at the mu receptor, flexible dosing and the ability to adjust to the needs of

an individual. Slide9

APPROPRIATE MODALITY

Physicians should consider:

Treatment history (poor response to buprenorphine in the past)

History of diversion

Severity of drug use

Patient reliability

Financial resources

Family support

Transportation issuesSlide10

Other Services provided:

Case management services

Individual Counseling

Group Counseling

Intensive Outpatient Services

Women’s Intensive Outpatient Services

Alcohol and Drug Education

Skills Development

Relapse Prevention

Assertiveness

Training

Stress and Anger Management

AA and NA Education and Developing a non-using support system

Urinalysis Screening

Referrals for Community Support Services

Transportation Needs

Co-occurring Disorders

HIV Testing and Counseling

Hepatitis C Testing and ReferralSlide11

Benefits of MAT

Medication-Assisted Treatment (MAT) with methadone, buprenorphine, or naloxone, has been proven to help patients recover from opioid addiction.

These medications are:

Safe

Cost-effective

Reduce the risk of overdose

Increase treatment retention

Improve social functioning

Reduce the risks of infectious disease transmission

Reduce criminal activity

*

When

researchers studied heroin-overdose deaths in Baltimore between 1995 and 2009, they found an association between increasing availability of MAT (methadone and buprenorphine) and an approximately 50% decrease in the number of fatal heroin overdoses.Slide12

Challenges of MAT

Negative stigma of MAT particularly methadone

Affects the attitudes of medical and healthcare professionals; social service agencies and workers; paraprofessionals

;

employers, families, and friends of persons who are opioid addicted; and others who formerly abused substances. Stigma has also influenced criminal justice policies, created political opposition and limited funding and space for OTPs.

Lack of access to opioid maintenance treatment.

Only

10 percent of the 23 million Americans with addictions and substance use disorders (SUD) receive any care in a given year. The lack of treatment access is also significant for justice-involved individuals – those in the courts, incarcerated, reentering society, or under community supervision like probation. Of the 2.4 million people currently in prison, an estimated 65 percent are clinically addicted to drugs or alcohol, but only 11 percent receive any professional treatment while

incarcerated.

 In addition, more than half of those on parole or probation continue to go untreated

.

Lack of training and education about MAT and its benefitsSlide13

More Challenges…

Medication-assisted treatment has saved many lives, but it is still not often accepted by the public

.

Patients seeking MAT for opioid use disorder sometimes find that their healthcare providers may have a negative opinion of MAT despite medical evidence of its many benefits.

Limited

number of licensed physicians prescribing buprenorphine.

While it can be dispensed in sublingual form in a physician’s office, unlike methadone, which requires patients to seek out treatment in a qualified methadone treatment center, it is not linked to counseling and other treatment services which are used to provide better outcomes for the patient. Slide14

MAT: Myths and FAQs

MAT just trades one addiction for

another

MAT bridges the biological and behavioral components of addiction. Research indicates that a combination of medication and behavioral therapies can successfully treat SUDs and help sustain recovery

.

MAT is only for the short

term.

Research

shows that patients on MAT for at least 1-2 years have the greatest rates of long-term success. There is currently no evidence to support benefits from cessation.

Patients

with long-term abstinence can follow a slow taper schedule under a physician’s direction, when free of stressors, to attempt dose reduction or total cessation.

“I’ve known a few people who could stop using opioids without help from any kind of medication. MAT is only for the weak. “

Though opioid abuse may begin with a series of poor judgments, addiction involves real, physical changes in the brain. While some people are eventually able to quit using opioids on their own, the majority of patients go though many dangerous cycles of relapse and recovery. MAT can make the recovery process much safer, and has saved many lives by preventing death from overdose or dangerous behaviors associated with “street” drug use.Slide15

MAT: Myths and FAQs

My patient’s condition is not severe enough to require MAT.

MAT

utilizes a multitude of different medication options (agonists, partial agonists and antagonists) that can be tailored to fit the unique needs of the

patient.

MAT

increases the risk for overdose in

patients.

MAT

helps to prevent overdoses from occurring. Even a single use of opioids after detoxification can result in a life-threatening or fatal overdose. Following detoxification, tolerance to the euphoria brought on by opioid use remains higher than tolerance to respiratory depression

.

Providing MAT will only disrupt and hinder a patient’s recovery process.

MAT has been shown to assist patients in recovery by improving quality of life, level of functioning and the ability to handle stress. Above all, MAT helps reduce mortality while patients begin recovery. Slide16

MAT: Myths and FAQs

There

isn’t any proof that MAT is better than

abstinence.

MAT

is evidence-based and is the recommended course of treatment for opioid addiction. The National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, National Institute on Alcohol Abuse and Alcoholism, Centers for Disease Control and Prevention, and other agencies emphasize MAT as first line treatment.

MAT is not effective because it does not immediately end drug dependence.

Opioid

use disorder or Addiction is not “cured” by the use of MAT. Addiction is a “chronic” (long-lasting) disease. Medical treatment for addiction can be

compared

to medical treatment for other common chronic diseases like diabetes or high blood pressure. Just as diabetes is not “cured” by the use of insulin, and people with high blood pressure often continue taking medications for many years, so people with opioid addiction are not “cured” but instead well-managed by MAT

.Slide17

MAT: Myths and FAQs

How long will I need to be on methadone,

suboxone

or

vivitrol

?

The length of treatment can vary from patient to patient. The decision to discontinue therapy with these medications after a period of maintenance should be made as part of a comprehensive treatment plan. It is up to you, your doctor, and your therapist or counselor to decide on the appropriate length of treatment.

Does

methadone,

suboxone

or

vivitrol

interact with other drugs or medications?

If you are taking any other prescription medications for physical or psychological reasons, make your physician aware prior to starting these medications. It is possible for these medications to negatively interact with other medications; therefore, it is important to discuss the use of other medications to avoid any adverse interactions. Slide18

MAT: Myths and FAQs

What if I no longer wish to take methadone? Can I stop or switch to a different medication?

Every individual who takes methadone is going to take it for a different length of time. If during your treatment, you wish to no longer take methadone or want to switch to a different medication, your treatment provider can assist you in tapering off methadone or prescribe another medication that can meet your needs. This process is necessary to prevent patients from experiencing adverse effects or withdrawal during this process. To learn more about ceasing the use of methadone or changing prescriptions, it is important to have a conversation with the doctor.

Most insurance plans don’t cover MAT.

As of May 2013, 31 state Medicaid FFS programs covered methadone maintenance treatment provided in outpatient programs. State Medicaid agencies vary as to whether

buprenorphine

is listed on the Preferred Drug List (PDL), and whether prior authorization is required (a distinction often made based on the specific

buprenorphine

medication type). Extended-release

naltrexone

is listed on the Medicaid PDL in over 60 percent of states. Slide19

MAT Success Stories and Outcomes

Outcome data

for

STS

MAT population

includes:

70%

R

eduction

in substance abuse

78%

C

ompliance

with treatment plan

goals

94%

R

eduction

of criminal

activity

Leonard’s recovery journey…

"Leonard" came into our agency in 2012, using 15-20

bags of

heroin intravenously on a daily basis. He was

unemployed and

living with an opiate-addicted woman. He had

various legal

charges, including an old DUI. Leonard had

been incarcerated

previously. After his admission to MAT, he still

used some

heroin sporadically during the first year. However, after a

year, he

began attending IOP services on a regular basis

. He

then attended weekly groups as well as individual

counseling. Leonard

has now been abstinent from illicit drugs for over two 

and

a half years. He is also gainfully employed and has

purchased a

home, in which he lives with a new girlfriend, who is also drug

free. Leonard

has chosen to utilized the available treatment tools of MAT, IOP, etc

. to

help him find a path toward successful long-term recovery.Slide20

MAT Success Stories and Outcomes

TLC Overall

Outcomes &

Reputation

*as of 12/31/17

70

%

of

respondents would recommend TLC to others.

81.5

%

of

respondents report life has improved since entering the program

.

71.5

%

of

UDS are negative of illicit drugs.

45%

of

patients have of length of stay of 2 years or more.

57.2%

of patients have

2 or more take home bottles

Ron’s recovery journey…

“Ron” came

to treatment on March 21,

2016. He is

a 73 Black male with (2) previous unsuccessful treatment that he admitted leaving AMA due to his withdrawals and not being able to pay for treatment.

He

receives SSD; he has Medicare which does not pay for OTP.

He came

to

TLC

and

requested admission

on the MATOP program because he suffers from COPD and Emphysema and his health was deteriorating due to his substance use disorder.

He started pulmonary treatment

regularly and since being on the MATOP his health has

improved. He receives

oxygen tanks weekly and

is now able

to have some mobility.

He

struggled with becoming drug free for the first 6 months in treatment

however since

then he has submitted

consecutive

negative urine drug screens.

Ron

has one sister that lives out of state which visits him regularly, reminding him that she is proud of him.

Ron is

grateful for the MATOP

program for giving

him a chance to become drug free, he is a Phase

5

client and comes to the clinic

2 times

a week and has his Individual Counseling Sessions 2 times a month.

Counselor has a cohesive relationship with medical professionals involved in

Ron’s care

and works collaboratively with them to ensure

he

can live a productive and healthy life.

He feels

a sense of accomplishment and hope, thanks to the efforts of the MATOP program and in particular his counselor and his sister who has been instrumental in his treatment

progress.Slide21

MAT Success Stories and Outcomes

Joe’s recovery journey…

“Joe” came

into treatment on December 29, 2015.

He

stated he came to treatment after hearing from some friends that

TLC

had a free program called MATOP.

Joe

was living with his mother in her living room couch before reconciling with his ex-wife.

He was

taking illicit substances such as Xanax,

Klonopin

and other illicit substances that were not prescribed to him.

He was

given a referral to our in-house psychiatrist and our psychotherapist.

Joe

was prescribed psychotropic medication and met with the mental health team weekly, which he reported he has helped him cope with major trauma he experienced with his father and other family members.

Joe’s wife

filed for divorce due to his addiction and losing the family business they had for

years.

Joe

has more than

20

months drug free since coming into treatment.

He has

been addressing his addiction, health and mental health issues. Recently

he was

diagnosed with Cirrhosis of the liver, and is currently on medication.

He

stated he is getting better with his

treatment and

was able to

establish

and amend his relationship with his ex wife who is very supportive of him now that he been drug free.

Joe recently

lost with mother due to her battle with cancer and dementia; he was there for her every step of the way through her transition last month.

Joe’s

ex-wife, which he lives with was recently diagnose with Lou Gehrig

disease

aka known as ALS.

He

has been accompanying her to her appointments in New York City at least two times a month.

While Joe has

been going through a lot

within the last 9 months, he

has chosen not to pick up any illicit substances to deal with life on life’s terms.

Joe

is currently a 6 take-home bottle

carrier

and comes to the clinic 1x per week with Individual Counseling Sessions 2x per month.

His counselor

has a cohesive relationship with the medical professionals involved in

his

care and works collaboratively with them to ensure

he can

live a productive and healthy life.

Joe

feels a sense of accomplishment and hope, thanks to the efforts of the MATOP program and in particular his primary counselor and medical professionals who have been instrumental in his treatment progress.

Joe

and his ex-wife are hoping to re marry by the beginning of the year.